The project has produced a steady stream of research papers in the field of neurodegenerative disease since 2003.


Vilariño-Güell C, Ross OA, Soto AI, Farrer MJ, Haugarvoll K, Aasly JO, Uitti RJ, Wszolek ZK. Reported mutations in GIGYF2 are not a common cause of Parkinson's disease. Mov Disord 2009 Jan 9. [Epub ahead of print]

Wider C, Dächsel JC, Soto AI, Heckman MG, Diehl NN, Yue M, Lincoln S, Aasly JO, Haugarvoll K, Trojanowski JQ, Papapetropoulos S, Mash D, Rajput A, Rajput AH, Gibson JM, Lynch T, Dickson DW, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA. FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov Disord 2009 Jan 9. [Epub ahead of print]


Corneveaux JJ, Liang WS, Reiman EM, Webster JA, Myers AJ, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Craig DW, Coon KD, Dunckley T, Bandy D, Lee W, Chen K, Beach TG, Mastroeni D, Grover A, Ravid R, Sando SB, Aasly JO, Heun R, Jessen F, Kölsch H, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Papassotiropoulos A, Stephan DA, Huentelman MJ. Evidence for an association between KIBRA and late-onset Alzheimer’s disease. Neurobiol Aging 2008; E-pub ahead of print.

Haugarvoll K, Toft M, Skipper L, Heckman MG, Crook JE, Soto A, Ross OA, Hulihan MM, Kachergus JM, Sando SB, White LR, Lynch T, Gibson JM, Uitti RJ, Wszolek ZK, Aasly JO, Farrer MJ. Fine-mapping and candidate gene investigation within the PARK10 locus. Eur J Hum Genet 2008 Oct 15. [Epub ahead of print]

Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-90.

Myhre R, Klungland H, Farrer MJ, Aasly JO. Genetic association study of synphilin-1 in idiopathic Parkinson's disease. BMC Med Genet. 2008;9:19.

Myhre R, Toft M, Kachergus J, Hulihan MM, Aasly JO, Klungland H, Farrer MJ. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol Scand 2008;118:320-7.

Ross OA, Heckman MG, Soto AI, Diehl NN, Haugarvoll K, Vilariño-Güell C, Aasly JO, Sando S, Gibson JM, Lynch T, Krygowska-Wajs A, Opala G, Barcikowska M, Czyzewski K, Uitti RJ, Wszolek ZK, Farrer MJ. Dopamine beta-hydroxylase -1021C>T association and Parkinson's disease. Parkinsonism Relat Disord 2008;14:544-7.

Ross OA, Soto AI, Vilariño-Güell C, Heckman MG, Diehl NN, Hulihan MM, Aasly JO, Sando S, Gibson JM, Lynch T, Krygowska-Wajs A, Opala G, Barcikowska M, Czyzewski K, Uitti RJ, Wszolek ZK, Farrer MJ. Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord 2008;14:539-43.

Sando SB, Melquist SB, Cannon A, Hutton M, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO. APOE¿4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case-control study from central Norway. BMC Neurology 2008;8:9.

Sando SB, Melquist SB, Cannon A, Hutton M, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO. Risk-reducing effect of education in Alzheimer's disease. Int J Geriatr Psychiatry 2008;23:1156-62.


Haugarvoll K, Toft M, Ross OA, Stone JT, Heckman MG, White LR, Lynch T, Gibson JM, Wszolek ZK, Uitti RJ, Aasly JO, Farrer MJ. ELAVL4, PARK10, and the Celts. Mov Disord 2007;22:585-7.

Haugarvoll K, Toft M, Ross OA, White LR, Aasly JO, Farrer MJ. Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. Neurosci Lett. 2007;416:299-301.

Kjelvik G, Sando SB, Aasly J, Engedal KA, White LR. Use of the Brief Smell Identification Test for olfactory deficit in a Norwegian population with Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:1020-4.

Pearson JV, Huentelman MJ, Halperin RF, Tembe WD, Melquist S, Homer N, Brun M, Szelinger S, Coon KD, Zismann VL, Webster JA, Beach T, Sando SB, Aasly JO, Heun R, Jessen F, Kolsch H, Tsolaki M, Daniilidou M, Reiman EM, Papassotiropoulos A, Hutton ML, Stephan DA, Craig DW. Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet 2007;80:126-39.

Ross OA, Haugarvoll K, Stone JT, Heckman MG, White LR, Aasly JO, Mark Gibson J, Lynch T, Wszolek ZK, Uitti RJ, Farrer MJ. Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease. Parkinsonism Relat Disord 2007;13:386-8.

Taylor JP, Hulihan MM, Kachergus JM, Melrose HL, Lincoln SJ, Hinkle KM, Stone JT, Ross OA, Hauser R, Aasly J, Gasser T, Payami H, Wszolek ZK, Farrer MJ. Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics 2007;8:95-102.

Toft M, Farrer MJ, Aasly JO, Dickson DW, Wszolek ZK. LRRK2 associated parkinsonism. In Mandel S, ed. Handbook of Neurochemistry and Molecular Neurobiology, vol 13. Springer 2007.

Toft M, Haugarvoll K, Ross OA, Farrer MJ, Aasly JO. LRRK2 and Parkinson's disease in Norway. Acta Neurol Scand Suppl. 2007;187:72-5.

Toft M, Mata IF, Ross OA, Kachergus J, Hulihan MM, Haugarvoll K, Stone JT, Blazquez M, Gibson JM, Aasly JO, White LR, Lynch T, Adler CH, Gwinn-Hardy K, Farrer MJ. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Mov Disord 2007;22:389-92.

Toft M, Myhre R, Pielsticker L, White LR, Aasly JO, Farrer MJ. PINK1 mutation heterozygosity and the risk of Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:82-4.

White LR, Toft M, Kvam SN, Farrer MJ, Aasly JO. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J Neurosci Res 2007;85:1288-94.


Gosal D, Ross OA, Toft M. Parkinson’s disease: the genetics of a heterogeneous disorder. Eur J Neurol 2006;13:616-27.

Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, Chartier-Harlin MC, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert JC, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan EK, Van Broeckhoven C; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006;296:661-70.

Papapetropoulos S, Singer C, Ross OA, Toft M, Johnson JL, Farrer MJ, Mash DC. Clinical heterogeneity of the LRRK2 G2019S mutation. Arch Neurol 2006;63:1242-6.

Ross OA, Toft M, Mash DC, Papapetropoulos S, Litvan I, Gordon MF, Johnson JL, Farrer MJ, Dickson DW. LRRK2 and Lewy body disease. Ann Neurol 2006;59:388-93.

Ross OA, Whittle AJ, Cobb SA, Hulihan M, Lincoln S, Toft M, Farrer MJ, Dickson D. The LRRK2 R1441 substitution and progressive supranuclear palsy. Neuropathol Appl Neurobiol 2006;32:23-5.

Toft M, Pielsticker L, Ross OA, Aasly J, Farrer M. Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006;66:415-7.


Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-5

Biancalana V, Toft M, Le Ber I, Thibodeau S, Tison F, Mandel JL, Brice A, Farrer M, Durr A. Multiple system atrophy is not associated with fragile X associated tremor/ataxia syndrome. Arch Neurol 2005; 62: 962-966.

Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, Mata IF, Kachergus J, Hulihan M, Taylor JP, Lincoln SJ, Farrer MJ, Lynch T, Gibson JM. Clinical traits of LRRK2 -associated Parkinson’s disease in Ireland: A link between familial and idiopathic PD. Parkinsonism Relat Disord 2005;11:349-52.

Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-80.

Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005;6:171-7.

Toft M, Aasly J, Bisceglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, Lynch T, Wszolek ZK, Farrer MJ. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord 2005;20:230-3.

Toft M, Farrer M. Premutation alleles and fragile X-associated tremor/ataxia syndrome. JAMA 2005;293:296; author reply 296-7.

Toft M, Farrer M. Genetics of Parkinson’s disease. In Galvez-Jimenez N, editor. The scientific basis for the treatment of Parkinson’s disease. Taylor & Francis Group; 2nd edition 2005; pp.121-9.

Toft M, Mata IF, Kachergus JM, Ross OA, Farrer MJ. LRRK2 mutations and Parkinsonism. Lancet 2005;365:1229-30.

Toft M, Sando SB, Melquist S, Ross OA, White LR, Aasly JO, Farrer MJ. LRRK2 mutations are not common in Alzheimer's disease. Mech Age Devel 2005;126:1201-5.


Skipper L, Wilkes K, Toft M, Baker M, Lincoln S, Hulihan M, Hutton M, Aasly J, Farrer M. Linkage disequilibrium and association of MAPT H1 in Parkinson's disease. Am J Hum Genet 2004;75:669-77.

Toft M, Aasly J. Genetikk ved Parkinsons sykdom. Tidsskr Nor Lægeforen 2004;124:922-24.

White LR, Gårseth M, Aasly J, Sonnewald U. Cerebrospinal fluid from patients with dementia contains increased amounts of an unknown factor. J Neurosci Res 2004;78:297-301.

Contact information

Project leader/ coordinator:
Professor Linda R. White , PhD

Clinical Leader:
Geir Bråthen, MD PhD
Department leader

Research leader: Alzheimer's disease
Sigrid Botne Sando , MD PhD
Senior Consulting Neurologist

Research leader: Parkinson disease
Professor Jan Aasly , MD PhD